Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Guttormsen, Anne B
Madsen, Kristian R
Møller, Morten H
Elkjær, Jeanie M
Poulsen, Lone M
White, Jonathan O
Thornberg, Klaus J
Andersen, Lasse H
Holst, Lars B
Fabritius, Maria L
Pott, Frank C
Møller, Thea P
MetadataShow full item record
CitationN. Engl. J. Med. 2012, 367 (2):124-34
AbstractHydroxyethyl starch (HES) [corrected] is widely used for fluid resuscitation in intensive care units (ICUs), but its safety and efficacy have not been established in patients with severe sepsis. In this multicenter, parallel-group, blinded trial, we randomly assigned patients with severe sepsis to fluid resuscitation in the ICU with either 6% HES 130/0.42 (Tetraspan) or Ringer's acetate at a dose of up to 33 ml per kilogram of ideal body weight per day. The primary outcome measure was either death or end-stage kidney failure (dependence on dialysis) at 90 days after randomization. Of the 804 patients who underwent randomization, 798 were included in the modified intention-to-treat population. The two intervention groups had similar baseline characteristics. At 90 days after randomization, 201 of 398 patients (51%) assigned to HES 130/0.42 had died, as compared with 172 of 400 patients (43%) assigned to Ringer's acetate (relative risk, 1.17; 95% confidence interval [CI], 1.01 to 1.36; P=0.03); 1 patient in each group had end-stage kidney failure. In the 90-day period, 87 patients (22%) assigned to HES 130/0.42 were treated with renal-replacement therapy versus 65 patients (16%) assigned to Ringer's acetate (relative risk, 1.35; 95% CI, 1.01 to 1.80; P=0.04), and 38 patients (10%) and 25 patients (6%), respectively, had severe bleeding (relative risk, 1.52; 95% CI, 0.94 to 2.48; P=0.09). The results were supported by multivariate analyses, with adjustment for known risk factors for death or acute kidney injury at baseline. Patients with severe sepsis assigned to fluid resuscitation with HES 130/0.42 had an increased risk of death at day 90 and were more likely to require renal-replacement therapy, as compared with those receiving Ringer's acetate. (Funded by the Danish Research Council and others; 6S ClinicalTrials.gov number, NCT00962156.)
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to The New England journal of medicine
- Hydroxyethyl starch in severe sepsis: end of starch era?
- Authors: Estrada CA, Murugan R
- Issue date: 2013 Mar 13
- Hydroxyethyl starch in sepsis.
- Authors: Haase NR
- Issue date: 2014 Jan
- Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate.
- Authors: Perner A, Haase N, Winkel P, Guttormsen AB, Tenhunen J, Klemenzson G, Müller RG, Aneman A, Wetterslev J
- Issue date: 2014 Jul
- Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis.
- Authors: Müller RB, Haase N, Lange T, Wetterslev J, Perner A
- Issue date: 2015 Mar
- Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial.
- Authors: Béchir M, Puhan MA, Fasshauer M, Schuepbach RA, Stocker R, Neff TA
- Issue date: 2013 Dec 23